Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Guin, Sunny ^a,b   Pollard, Courtney ^a,b   Ru, Yuanbin ^a,b,k   Lew, Carolyn Ritterson ^a,b   Duex, Jason E ^a,b   Dancik, Garrett ^a,b   Owens, Charles ^a,b   Spencer, Andrea ^c,d   Knight, Scott ^c,d   Holemon, Heather ^c,d   Gupta, Sounak ^e   Hansel, Donna ^e   Hellerstein, Marc ^f,g   Lorkiewicz, Pawel ^h   Lane, Andrew N ⁱ   Fan, Teresa W M ^a   Theodorescu, Dan ^a,b,j  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Sigma Aldrich Co   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF LOUISVILLE   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j WINDBER RESEARCH INSTITUTE   (United States)

^k EASTERN CONNECTICUT STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLO ALPHA 1,6 GLUCOSIDASE, 4 ALPHA GLUCANOTRANSFERASE; GLYCINE HYDROXYMETHYLTRANSFERASE; GLYCINE HYDROXYMETHYLTRANSFERASE 2; GLYCOGEN DEBRANCHING ENZYME; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENETIC ASSOCIATION; GLYCOGENOLYSIS; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RNA INTERFERENCE; ANIMAL; BLADDER TUMOR; ENZYMOLOGY; GENETICS; GLYCOGEN STORAGE DISEASE; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENOME-WIDE ASSOCIATION STUDY; GLYCOGEN DEBRANCHING ENZYME SYSTEM; GLYCOGEN STORAGE DISEASE; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, NUDE; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 84904061817     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju062     Document Type: Article

References (43)

1. Gregory MA, Phang TL, Neviani P, et al. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010;18(1):74-87.
2. Coussens MJ, Corman C, Fischer AL, et al. MISSION LentiPlex pooled shRNA library screening in mammalian cells. J Vis Exp. 2011;58. doi:10.3791/3305.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
4. Gildea JJ, Golden WL, Harding MA, et al. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer. 2000;27(3):252-263.
5. Nitz MD, Harding MA, Smith SC, et al. RREB1 transcription factor splice variants in urologic cancer. Am J Pathol. 2011;179(1):477-486.
6. Wang H, Owens C, Chandra N, et al. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res. 2010;70(21):8760- 8769.
7. Hansel DE, Platt E, Orloff M, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010;176(6):3062-3072.
8. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006;38(12):1386-1396.
9. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
10. Kim W-J, Kim E-J, Kim S-K, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9(1):3.
11. Sanchez-Carbayo M, Socci ND, Lozano J, et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligo-nucleotide microarrays. J Clin Oncol. 2006;24(5):778-789.
12. Blaveri E, Simko J P, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11(11):4044- 4055.
13. Pinheiro J, Bates D, DebRoy S, et al. nlme: Linear and Nonlinear Mixed Effects Models. In: Team RDC, (ed). R package version 3.1-102; 2011.
14. Illa-Bochaca I, Fernandez-Gonzalez R, Shelton DN, et al. Limiting-dilution transplantation assays in mammary stem cell studies. Methods Mol Biol. 2010;621:29-47.
15. Demo E, Frush D, Gottfried M, et al. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol. 2007;46(3):492-498.
16. Dagli A, Sentner C P, Weinstein WA. Glycogen Storage Disease Type III. Seattle: University of Washington; 2011.
17. Hicks J, Wartchow E, Mierau G. Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol. 2011;35(5):183-196.
18. Roach PJ, Depaoli-Roach AA, Hurley TD, et al. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012;441(3):763-787.
19. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040-1044.
20. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3:e248.
21. Cheng A, Zhang M, Okubo M, et al. Distinct mutations in the gly-cogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions. Hum Mol Genet. 2009;18(11):2045-2052.
22. Cheng A, Zhang M, Gentry MS, et al. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev. 2007;21(19):2399-2409.
23. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309- 314.
24. Brown J. Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat. Metabolism. 1962;11:1098-1112.
25. Fan TW, Lane AN, Higashi RM, et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.
26. Fan TW-M, Yuan P, Lane AN, et al. Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics. 2010;6(2):165-179.
27. Fan T, Lane A, Higashi R, et al. Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics 2011;7(2):257-269.
28. Lane AN, Fan TW, Bousamra M, et al. Stable isotope-resolved metabo-lomics (SIRM) in cancer research with clinical application to nonsmall cell lung cancer. OMICS. 2011;15(3):173-182.
29. Lane AN, Fan TW-M, Higashi RM, et al. Stable isotope tracing in metabolic pathways. Presentation given at JG Brown Cancer Center, University of Louisville, KY. 7-11 April 2008.
30. Moseley H, Lane A, Belshoff A, et al. A novel deconvolution method for modeling UDP-GlcNAc biosynthetic pathways based on 13C mass isotopo-logue profiles under non steady-state conditions. BMC Biol. 2011;9(1):37.
31. Fan TW-M, Ta n JL, McKinney MM, et al. Stable isotope resolved metab-olomics analysis of ribonucleotide and rna metabolism in human lung cancer cells. Metabolomics. 2012;8(3):517-527.
32. Lorkiewicz P, Higashi RM, Lane AN, et al. High information throughput analysis of nucleotides and their isotopically enriched isotopologues by direct-infusion FTICR-MS. Metabolomics. 2012;8(5):930-939.
33. Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry. 2nd ed. New York: W. H. Freeman; 1993.
34. Murray RK, Mayes PA, Rodwell VW, Granner, DK. Harper's Illustrated Biochemistry. 26th ed. New York: McGraw-Hill; 2003.
35. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
36. Kalhan SC, Hanson RW. Resurgence of serine: an often neglected but indispensable amino acid. J Biol Chem 2012;287(24):19786-19791.
37. Hebbring SJ, Chai Y, Ji Y, et al. Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J Neurochem. 2012;120(6):881-890.
38. Chen YT, Burhchell A, Scriver CR, et al. The Metabolomic and Molecular Basis of Inherited Disease. New York: McGraw-Hill.
39. Greenberg CC, Jurczak MJ, Danos AM, et al. Glycogen branches out: new perspectives on the role of glycogen metabolism in the integration of metabolic pathways. Am J Physiol Endocrinol Metab. 2006;291(1):E1-E8.
40. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006;5:17.
41. Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates beta-catenin transacti-vation upon EGFR activation. Nature. 2011;480(7375):118-122.
42. Ritterson Lew C, Tolan DR. Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J Biol Chem. 2012;287(51):42554-42563.
43. Furuta E, Okuda H, Kobayashi A, et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta. 2010;1805(2):141-152.